May 3rd 2024
Findings from a real-world study identified that venetoclax was a safe treatment option and did not lead to higher rates of death for patients with chronic lymphocytic leukemia who were diagnosed with COVID-19.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
SEQUOIA Study Update: Zanubrutinib Prolongs PFS in Chronic Lymphocytic Leukemia
July 30th 2021Treatment with zanubrutinib in patients with treatment-naive chronic lymphocytic leukemia led to a significant improvement in progression-free survival, meeting the primary end point of the phase 3 SEQUOIA clinical trial.
Read More
Venugopal Considers BTK and BCL2 Inhibitors in Patient With CLL
July 22nd 2021Treatment for a patient with chronic lymphocytic leukemia who has comorbidities including hypertension and atrial fibrillation was the topic of discussion during a Targeted Oncology Case-Based Roundtable event led by Parameswaran Venugopal, MD.
Read More
Ibrutinib Bests Chlorambucil in Elderly Patients with Treatment-Naïve CLL/SLL
July 1st 2021Paul Barr, MD, discusses the results of the RESONATE-2, which evaluates efficacy of the Bruton’s tyrosine kinase inhibitor, ibrutinib versus chlorambucil in patients who are 65 years old or older with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Watch
Responses to Zanubrutinib Monotherapy Continue and Deepen in CLL, Updated Results Show
June 16th 2021With longer follow-up, significant responses were still observed with the BTK inhibitor zanubrutinib as a single agent in patients with relapsed or refractory chronic lymphocytic leukemia in the phase 2 BGB-3111-205 trial.
Read More
Frontline Venetoclax and Obinutuzumab Maintains Delay of Progression in CLL
June 15th 2021With further follow-up from the phase 3 CLL14 trial, the median progression-free survival was still reached with the fixed-dose regimen of venetoclax and obinutuzumab in patients with previously untreated chronic lymphocytic leukemia.
Read More
Responses Achieved With Zandelisib/Zanubrutinib in R/R CLL, B-Cell Lymphomas
June 14th 2021A combination of zandelisib and zanubrutinib induced significant responses, including several complete responses in patients with relapsed or refractory chronic lymphocytic leukemia and other B-cell lymphomas in a phase 1b study, the results of which were presented during the 2021 European Hematology Association Annual Congress.
Read More
Acalabrutinib Mirrors PFS Results of Ibrutinib in Frontline CLL
June 14th 2021In an interview with Targeted Oncology, Peter Hillmen, MD, PhD, discussed the results of the head-to-head trial comparing acalabrutinib and ibrutinib, as well as future directions for Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia.
Read More
Fixed-Duration Ibrutinib/Venetoclax Shows Greater PFS in CLL
June 12th 2021A fixed duration of ibrutinib plus venetoclax led to a significant progression-free survival benefit over chlorambucil plus obinutuzumab as frontline treatment in patients with chronic lymphocytic leukemia, according to a primary analysis of the phase 3 GLOW study presented at the European Hematology Association 2021 Virtual Congress.
Read More
First-Line Treatment Ibrutinib Plus Venetoclax Inhibits Response in CLL/SLL
June 7th 2021Over half, 56%, of patients with chronic lymphocytic leukemia and small lymphocytic lymphoma who were treated with The combination of ibrutinib plus venetoclax produced a complete response and complete response with incomplete bone marrow recovery
Read More
Frontline Ibrutinib/Venetoclax Combination Induces Responses in CLL/SLL
June 7th 2021Patients with chronic lymphocytic leukemia and small lymphocytic lymphoma treated with the combination of ibrutinib plus venetoclax had complete response and complete response with a 56% incomplete bone marrow recover rate in the phase 2 CAPTIVATe study.
Read More
Frontline Ibrutinib Sustains OS Benefit in Chronic Lymphocytic Leukemia
June 5th 2021Based on 7-year follow-up data, the use of front-line ibrutinib monotherapy has sustained progression-free survival and overall survival benefit compared with chlorambucil as treatment of patients with chronic lymphocytic leukemia.
Read More